JP2017514517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514517A5 JP2017514517A5 JP2017507920A JP2017507920A JP2017514517A5 JP 2017514517 A5 JP2017514517 A5 JP 2017514517A5 JP 2017507920 A JP2017507920 A JP 2017507920A JP 2017507920 A JP2017507920 A JP 2017507920A JP 2017514517 A5 JP2017514517 A5 JP 2017514517A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- affinity chromatography
- chromatography matrix
- composition
- selection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 83
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 34
- 238000000034 method Methods 0.000 claims 31
- 238000001042 affinity chromatography Methods 0.000 claims 29
- 239000012504 chromatography matrix Substances 0.000 claims 29
- 239000000203 mixture Substances 0.000 claims 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims 20
- 239000003153 chemical reaction reagent Substances 0.000 claims 15
- 102000006306 Antigen Receptors Human genes 0.000 claims 12
- 108010083359 Antigen Receptors Proteins 0.000 claims 12
- 239000011230 binding agent Substances 0.000 claims 9
- 238000011534 incubation Methods 0.000 claims 9
- 230000004936 stimulating effect Effects 0.000 claims 7
- 239000002458 cell surface marker Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 108091008874 T cell receptors Proteins 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000011159 matrix material Substances 0.000 claims 3
- 230000000638 stimulation Effects 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 238000002617 apheresis Methods 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 230000002441 reversible effect Effects 0.000 claims 2
- 238000000926 separation method Methods 0.000 claims 2
- 239000002699 waste material Substances 0.000 claims 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 108010041397 CD4 Antigens Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 238000011467 adoptive cell therapy Methods 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461983415P | 2014-04-23 | 2014-04-23 | |
| US61/983,415 | 2014-04-23 | ||
| PCT/US2015/027401 WO2015164675A1 (en) | 2014-04-23 | 2015-04-23 | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020095186A Division JP7181910B2 (ja) | 2014-04-23 | 2020-06-01 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514517A JP2017514517A (ja) | 2017-06-08 |
| JP2017514517A5 true JP2017514517A5 (cg-RX-API-DMAC7.html) | 2018-06-07 |
| JP6759187B2 JP6759187B2 (ja) | 2020-09-23 |
Family
ID=53055126
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017507920A Active JP6759187B2 (ja) | 2014-04-23 | 2015-04-23 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
| JP2020095186A Active JP7181910B2 (ja) | 2014-04-23 | 2020-06-01 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
| JP2021135398A Active JP7503035B2 (ja) | 2014-04-23 | 2021-08-23 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
| JP2024043330A Active JP7675243B2 (ja) | 2014-04-23 | 2024-03-19 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
| JP2025072785A Pending JP2025108747A (ja) | 2014-04-23 | 2025-04-25 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020095186A Active JP7181910B2 (ja) | 2014-04-23 | 2020-06-01 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
| JP2021135398A Active JP7503035B2 (ja) | 2014-04-23 | 2021-08-23 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
| JP2024043330A Active JP7675243B2 (ja) | 2014-04-23 | 2024-03-19 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
| JP2025072785A Pending JP2025108747A (ja) | 2014-04-23 | 2025-04-25 | 養子療法用の免疫細胞集団を単離、培養、および遺伝子操作するための方法 |
Country Status (21)
Families Citing this family (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010045659A1 (en) | 2008-10-17 | 2010-04-22 | American Gene Technologies International Inc. | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| US10228312B2 (en) | 2012-02-23 | 2019-03-12 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| PT3132247T (pt) | 2014-04-16 | 2021-11-03 | Juno Therapeutics Gmbh | Métodos, kits e aparelho para ampliar uma população de células |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| ES2708584T3 (es) * | 2014-04-24 | 2019-04-10 | Miltenyi Biotec Gmbh | Método para la generación automatizada de células T modificadas genéticamente |
| CA3017170C (en) * | 2014-09-17 | 2021-03-23 | The Johns Hopkins University | Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells |
| SG10202002324SA (en) | 2014-11-05 | 2020-05-28 | Juno Therapeutics Inc | Methods for transduction and cell processing |
| US11896614B2 (en) | 2015-04-17 | 2024-02-13 | Novartis Ag | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| WO2017007994A1 (en) | 2015-07-08 | 2017-01-12 | American Gene Technologies International Inc. | Hiv pre-immunization and immunotherapy |
| SG10201912978PA (en) | 2015-07-21 | 2020-02-27 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| WO2017068419A2 (en) | 2015-10-22 | 2017-04-27 | Juno Therapeutics Gmbh | Methods, kits, agents and apparatuses for transduction |
| MA45489A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés de culture de cellules, kits et appareil associés |
| US20190269727A1 (en) * | 2015-12-28 | 2019-09-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| AU2017207906B2 (en) | 2016-01-15 | 2021-03-11 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| US10888613B2 (en) | 2016-02-08 | 2021-01-12 | American Gene Technologies International Inc. | Method of producing cells resistant to HIV infection |
| EP3426777B1 (en) | 2016-03-09 | 2022-02-16 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| EP3430549A1 (en) | 2016-03-16 | 2019-01-23 | Juno Therapeutics, Inc. | Methods for adaptive design of a treatment regimen and related treatments |
| JP7173548B2 (ja) | 2016-06-08 | 2022-11-16 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 非組み込みウイルス送達系およびその関連方法 |
| EP3481418A4 (en) | 2016-07-08 | 2020-03-11 | American Gene Technologies International Inc. | PRE-IMMUNIZATION AND IMMUNOTHERAPY OF HIV |
| WO2018017882A1 (en) | 2016-07-21 | 2018-01-25 | American Gene Technologies International Inc. | Viral vectors for treating parkinson's disease |
| AU2017322752A1 (en) | 2016-09-12 | 2019-03-21 | Juno Therapeutics, Inc. | Perfusion bioreactor bag assemblies |
| CA3041068A1 (en) | 2016-10-18 | 2018-04-26 | Regents Of The University Of Minnesota | Tumor infiltrating lymphocytes and methods of therapy |
| WO2018102761A1 (en) * | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
| MX2019006438A (es) * | 2016-12-05 | 2019-11-28 | Juno Therapeutics Inc | Produccion de celulas modificadas para terapia de celulas adoptivas. |
| JP7061125B2 (ja) | 2016-12-16 | 2022-04-27 | ダイアグノロジックス・エルエルシー | 浮力による分離方法およびシステム |
| EP4353818A3 (en) | 2017-02-27 | 2024-06-19 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
| KR102771581B1 (ko) | 2017-03-14 | 2025-02-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | 극저온 보관 방법 |
| JOP20190224A1 (ar) * | 2017-03-29 | 2019-09-26 | Iovance Biotherapeutics Inc | عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي |
| JP2020512815A (ja) | 2017-04-03 | 2020-04-30 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | フェニルケトン尿症を処置するための組成物および方法 |
| CN110709700A (zh) | 2017-04-14 | 2020-01-17 | 朱诺治疗学股份有限公司 | 评估细胞表面糖基化的方法 |
| WO2018197949A1 (en) | 2017-04-27 | 2018-11-01 | Juno Therapeutics Gmbh | Oligomeric particle reagents and methods of use thereof |
| US11413310B2 (en) * | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| JP7245177B2 (ja) | 2017-06-07 | 2023-03-23 | シージェン インコーポレイテッド | 低減した表面フコシル化を有するｔ細胞、及びそれを作製及び使用する方法 |
| CN111511375A (zh) | 2017-06-30 | 2020-08-07 | 因提玛生物科学公司 | 用于基因治疗的腺相关病毒载体 |
| WO2019011879A1 (en) | 2017-07-09 | 2019-01-17 | Rainer Henning | THERAPEUTIC AGENT FOR THE TREATMENT OF CAPILLARY LEAK SYNDROME |
| SG11202000425QA (en) * | 2017-07-21 | 2020-02-27 | Berkeley Lights Inc | Antigen-presenting synthetic surfaces, covalently functionalized surfaces, activated t cells, and uses thereof |
| AU2018313950A1 (en) | 2017-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| KR20250096881A (ko) * | 2017-08-09 | 2025-06-27 | 주노 쎄러퓨티크스 인코퍼레이티드 | 유전자 조작된 세포를 제조하기 위한 방법 및 조성물 |
| KR102296580B1 (ko) * | 2017-09-01 | 2021-09-02 | 론자 워커스빌 아이엔씨. | 엔드-투-엔드 세포 요법의 자동화 |
| WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY |
| US20200331975A1 (en) * | 2017-10-20 | 2020-10-22 | Institut Curie | Dap10/12 based cars adapted for rush |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| US20210254000A1 (en) | 2017-11-01 | 2021-08-19 | Juno Therapeutics, Inc. | Process for producing a t cell composition |
| DK3704230T3 (da) | 2017-11-01 | 2025-01-02 | Juno Therapeutics Inc | Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler |
| EP3706904A1 (en) | 2017-11-10 | 2020-09-16 | Juno Therapeutics, Inc. | Closed-system cryogenic vessels |
| AU2018375738A1 (en) * | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| KR102853341B1 (ko) | 2017-12-08 | 2025-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작된 ｔ 세포의 조성물을 제조하는 방법 |
| JP2021505615A (ja) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | 細胞療法および関連方法のための表現型マーカー |
| SG11202005228YA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Serum-free media formulation for culturing cells and methods of use thereof |
| JP2021519069A (ja) * | 2018-03-27 | 2021-08-10 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | 遺伝子改変リンパ球の製造方法 |
| CA3094375A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Use of histone modifiers to reprogram effector t cells |
| US12473532B2 (en) | 2018-05-10 | 2025-11-18 | Iovance Biotherapeutics, Inc. | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy |
| AU2019275076B2 (en) | 2018-05-23 | 2024-12-19 | National University Of Singapore | Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies |
| CN110643577A (zh) * | 2018-06-26 | 2020-01-03 | 深圳市北科生物科技有限公司 | 基于机械臂的全自动细胞培养方法及其系统 |
| EA202190469A1 (ru) | 2018-08-09 | 2021-06-28 | Джуно Терапьютикс, Инк. | Способы оценки интегрированных нуклеиновых кислот |
| WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| JP7504891B2 (ja) | 2018-09-11 | 2024-06-24 | ジュノー セラピューティクス インコーポレイテッド | 操作された細胞組成物のマススペクトロメトリー分析のための方法 |
| WO2020061696A1 (en) | 2018-09-28 | 2020-04-02 | Octane Biotech Inc. | Magnetic separation |
| CA3117568A1 (en) * | 2018-10-31 | 2020-05-07 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| CA3117720A1 (en) * | 2018-11-06 | 2020-05-14 | Juno Therapeutics, Inc. | Process for producing genetically engineered t cells |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| MX2021006244A (es) | 2018-11-30 | 2021-09-10 | Juno Therapeutics Inc | Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva. |
| EP3886875B1 (en) | 2018-11-30 | 2024-05-08 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| CA3123449A1 (en) | 2018-12-21 | 2020-06-25 | Lonza Walkersville, Inc. | Automated production of viral vectors |
| CN113366099B (zh) | 2018-12-21 | 2024-11-15 | 奥克泰生物科技股份有限公司 | 用于模块化生物生产单元的转盘 |
| TWI732357B (zh) * | 2018-12-27 | 2021-07-01 | 財團法人工業技術研究院 | 細胞培養裝置及方法 |
| JP2022518934A (ja) * | 2019-01-29 | 2022-03-17 | ジーピービー・サイエンティフィック・インコーポレイテッド | 向上した生産性および医薬的特徴を持つ細胞集団 |
| CN113498432A (zh) | 2019-02-08 | 2021-10-12 | 隆萨沃克斯维尔股份有限公司 | 用于自动化生物反应器的细胞浓缩方法和装置 |
| CN118546959A (zh) | 2019-03-05 | 2024-08-27 | 恩卡尔塔公司 | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 |
| DE102019108125B4 (de) * | 2019-03-28 | 2022-02-03 | Immatics US, Inc. | Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung |
| WO2020198299A1 (en) * | 2019-03-26 | 2020-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for characterizing and treating alzheimer's disease |
| US11464802B2 (en) | 2019-04-09 | 2022-10-11 | Nurix Therapeutics, Inc. | 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| US11530229B2 (en) | 2019-05-17 | 2022-12-20 | Nurix Therapeutics, Inc. | Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof |
| WO2020236850A1 (en) * | 2019-05-20 | 2020-11-26 | Immunovalent Therapeutics Inc. | Solid phase devices and methods of use for purifying and quantifying tissue-specific leukocytes |
| CN114269371A (zh) | 2019-06-12 | 2022-04-01 | 朱诺治疗学股份有限公司 | 细胞介导的细胞毒性疗法与促存活bcl2家族蛋白的抑制剂的组合疗法 |
| CN110358734B (zh) * | 2019-06-13 | 2020-08-25 | 首都医科大学宣武医院 | 以Tcm为主要效应成分的CAR-T制备方法及其应用 |
| CN114364670B (zh) | 2019-06-26 | 2025-06-13 | 纽力克斯治疗公司 | 用于Cbl-b抑制的取代苄基-三唑类化合物及其进一步用途 |
| EP4003965A1 (en) | 2019-07-30 | 2022-06-01 | Nurix Therapeutics, Inc. | Urea, amide, and substituted heteroaryl compounds for cbl-b inhibition |
| CN114555112A (zh) | 2019-08-22 | 2022-05-27 | 朱诺治疗学股份有限公司 | T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法 |
| KR20220073738A (ko) | 2019-08-30 | 2022-06-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 분류를 위한 기계 학습 방법 |
| IL292409A (en) | 2019-10-24 | 2022-06-01 | Octane Biotech Inc | A cell culture chamber with enhanced cell contact surfaces |
| US20250237628A1 (en) | 2019-10-30 | 2025-07-24 | Juno Therapeutics Gmbh | Cell selection and/or stimulation devices and methods of use |
| JP2022554348A (ja) | 2019-11-05 | 2022-12-28 | ジュノー セラピューティクス インコーポレイテッド | 治療用ｔ細胞組成物の属性を決定する方法 |
| KR20220097457A (ko) | 2019-11-11 | 2022-07-07 | 론자 워커스빌 아이엔씨. | 자동화된 세포 처리를 위한 품질 관리 방법 |
| CN115398231A (zh) | 2019-12-06 | 2022-11-25 | 朱诺治疗学股份有限公司 | 与治疗b细胞恶性肿瘤的细胞疗法相关的毒性和反应的相关方法 |
| KR20220123463A (ko) * | 2020-01-10 | 2022-09-06 | 론자 워커스빌 아이엔씨. | 생물학적 공정 및 세포 집단을 정제하기 위한 필터 장치 및 방법 |
| EP4093433A1 (en) | 2020-01-24 | 2022-11-30 | Juno Therapeutics, Inc. | Methods for dosing and treatment of follicular lymphoma and marginal zone lymphoma in adoptive cell therapy |
| WO2021163391A1 (en) | 2020-02-12 | 2021-08-19 | Juno Therapeutics, Inc. | Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
| CN115361955A (zh) | 2020-02-12 | 2022-11-18 | 朱诺治疗学股份有限公司 | 针对bcma的嵌合抗原受体t细胞组合物及其方法和用途 |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| AU2021262748A1 (en) * | 2020-04-27 | 2022-12-01 | Memorial Sloan-Kettering Cancer Center | Chimeric antigen receptors targeting CD127 and use thereof |
| KR20230022868A (ko) | 2020-05-13 | 2023-02-16 | 주노 쎄러퓨티크스 인코퍼레이티드 | 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법 |
| EP4150640A1 (en) | 2020-05-13 | 2023-03-22 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
| AU2021305084A1 (en) | 2020-07-07 | 2023-02-02 | Cancure, Llc | MIC antibodies and binding agents and methods of using the same |
| US20240392226A1 (en) * | 2020-10-12 | 2024-11-28 | Life Technologies As | Magnetic particle processing systems for use with biological cells and related methods |
| US12415982B2 (en) * | 2020-10-23 | 2025-09-16 | Applied Materials, Inc. | Automated closed system for cell therapy manufacturing |
| WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
| US12234473B2 (en) | 2020-12-31 | 2025-02-25 | Immatics US, Inc. | CD8 polypeptides, compositions, and methods of using thereof |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| AU2022246593A1 (en) | 2021-03-29 | 2023-10-12 | Juno Therapeutics, Inc. | Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy |
| US20250283037A1 (en) | 2021-05-06 | 2025-09-11 | Juno Therapeutics Gmbh | Methods for stimulating and transducing t cells |
| CN113388042B (zh) * | 2021-06-28 | 2022-02-01 | 北京鼎成肽源生物技术有限公司 | 一种重组蛋白、重组表达载体、重组细胞和nk细胞激活磁珠及其制备方法和应用 |
| WO2023015310A2 (en) * | 2021-08-06 | 2023-02-09 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | T-cell manufacturing methods |
| JP7328465B2 (ja) * | 2021-08-17 | 2023-08-16 | 日揮株式会社 | 演算装置、制御装置、培養システム、及び培養システムの設計方法 |
| CN114478726B (zh) * | 2022-02-14 | 2023-09-05 | 西南大学 | 链霉亲和素第27位丝氨酸突变的突变蛋白及其应用 |
| CN114507274B (zh) * | 2022-02-14 | 2023-08-25 | 西南大学 | 可逆结合生物素的链霉亲和素突变蛋白及其应用 |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| CA3257334A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | PRODUCTION OF VIRAL PARTICLES |
| EP4532695A1 (en) | 2022-05-25 | 2025-04-09 | Celgene Corporation | Methods of manufacturing t cell therapies |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4543923A1 (en) | 2022-06-22 | 2025-04-30 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
| CN120475987A (zh) | 2022-11-04 | 2025-08-12 | 优莫佳生物制药股份有限公司 | 多核苷酸构建体以及相关的病毒载体和方法 |
| EP4615960A1 (en) | 2022-11-09 | 2025-09-17 | C3S2 GmbH | Methods for manufacturing engineered immune cells |
| KR20250121074A (ko) | 2022-12-09 | 2025-08-11 | 주노 쎄러퓨티크스 인코퍼레이티드 | 홀로그래픽 이미징을 사용하여 세포 표현형을 예측하기 위한 기계 학습 방법 |
| EP4658675A1 (en) | 2023-02-03 | 2025-12-10 | C3S2 GmbH | Methods for non-viral manufacturing of engineered immune cells |
| IL322815A (en) | 2023-02-28 | 2025-10-01 | Juno Therapeutics Inc | Cell therapy for the treatment of systemic autoimmune diseases |
| CN116640192B (zh) * | 2023-04-12 | 2024-08-02 | 西南大学 | 链霉亲和素突变体StrepTactin的Y43A突变蛋白及其应用 |
| WO2024220588A1 (en) | 2023-04-18 | 2024-10-24 | Juno Therapeutics, Inc. | Cytotoxicity assay for assessing potency of therapeutic cell compositions |
| WO2024226858A1 (en) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Methods for viral vector manufacturing |
| WO2024238153A1 (en) | 2023-05-15 | 2024-11-21 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| WO2024243365A2 (en) | 2023-05-23 | 2024-11-28 | Juno Therapeutics, Inc. | Activation markers of t cells and method for assessing t cell activation |
| WO2025072081A1 (en) * | 2023-09-25 | 2025-04-03 | The Cleveland Clinic Foundation | Enriched t-cell populations |
| US20250215384A1 (en) * | 2023-12-31 | 2025-07-03 | Trenchant BioSystems, Inc. | Automated quality control and aseptic transfers in a cell processing system |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2025235851A1 (en) | 2024-05-10 | 2025-11-13 | Juno Therapeutics, Inc. | Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy |
Family Cites Families (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (cg-RX-API-DMAC7.html) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| ES2067018T3 (es) | 1988-12-28 | 1995-03-16 | Stefan Miltenyi | Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| ATE159548T1 (de) | 1990-11-13 | 1997-11-15 | Immunex Corp | Bifunktionelle wählbare fusionsgene |
| DE4237113B4 (de) | 1992-11-03 | 2006-10-12 | "Iba Gmbh" | Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| EP0804590A1 (en) | 1993-05-21 | 1997-11-05 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| DE69434342T2 (de) | 1993-06-04 | 2006-03-16 | The United States Of America Represented By The Secretary Of The Navy | Verfahren zur selektiven Stimulierung der T-Zellproliferation. |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US6022951A (en) | 1995-04-11 | 2000-02-08 | Univ Boston | Streptavidin mutants |
| US5801115A (en) | 1995-09-05 | 1998-09-01 | Kataleuna Gmbh | Catalyst composition and methods for using and preparing same |
| US5773224A (en) * | 1996-02-12 | 1998-06-30 | Grandics; Peter | Immunoselection system for cell elution |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| DE19641876B4 (de) | 1996-10-10 | 2011-09-29 | Iba Gmbh | Streptavidinmuteine |
| US5985658A (en) | 1997-11-14 | 1999-11-16 | Health Research Incorporated | Calmodulin-based cell separation technique |
| JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| US6664042B1 (en) | 1999-01-26 | 2003-12-16 | Cornell Research Foundation, Inc. | Determining viral load in double negative T cells |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| EP1227321A1 (en) | 2000-12-28 | 2002-07-31 | Institut für Bioanalytik GmbH | Reversible MHC multimer staining for functional purification of antigen-specific T cells |
| DE10113776B4 (de) | 2001-03-21 | 2012-08-09 | "Iba Gmbh" | Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| EP1630171B1 (de) | 2002-03-01 | 2007-08-15 | Volker A. Erdmann | Streptavidin-Bindungspeptid |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7754155B2 (en) | 2002-03-15 | 2010-07-13 | Ross Amelia A | Devices and methods for isolating target cells |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| FR2841905B1 (fr) | 2002-07-05 | 2004-09-03 | Centre Nat Rech Scient | Fragments fab mutants de l'anticorps anti-cd4 chimere 13b8.2 et leurs applications |
| EP1569510B1 (en) | 2002-09-27 | 2011-11-02 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
| PT1558648E (pt) | 2002-10-17 | 2012-04-23 | Genmab As | Anticorpos monoclonais humanos contra cd20 |
| SG150387A1 (en) | 2003-05-02 | 2009-03-30 | Insception Bioscience Inc | Apparatus and methods for amplification of blood stem cell numbers |
| US7943393B2 (en) | 2003-07-14 | 2011-05-17 | Phynexus, Inc. | Method and device for extracting an analyte |
| EP1648512A4 (en) | 2003-07-31 | 2009-01-21 | Immunomedics Inc | ANTI-CD19 ANTIBODIES |
| AU2004292131A1 (en) | 2003-11-20 | 2005-06-02 | Biosensor Applications Sweden (Publ) | Mixture of at least two different antibodies specific for predetermined antigens and use of the mixture |
| SE0400181D0 (sv) | 2004-01-29 | 2004-01-29 | Gyros Ab | Segmented porous and preloaded microscale devices |
| DK1766400T3 (da) | 2004-06-03 | 2009-07-20 | Meso Scale Technologies Llc | Fremgangsmåde til at udföre fuldblodsanalyser |
| WO2006044650A2 (en) | 2004-10-15 | 2006-04-27 | Genencor International, Inc. | Competitive differential screening |
| EP1827604B1 (en) | 2004-12-10 | 2019-11-20 | Peter MacCallum Cancer Institute | Methods and compositions for adoptive immunotherapy |
| US20060252087A1 (en) | 2005-01-18 | 2006-11-09 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
| CN101282993A (zh) | 2005-06-02 | 2008-10-08 | 阿斯利康公司 | 针对cd20的抗体和其用途 |
| US7855057B2 (en) | 2006-03-23 | 2010-12-21 | Millipore Corporation | Protein splice variant/isoform discrimination and quantitative measurements thereof |
| WO2007117602A2 (en) * | 2006-04-07 | 2007-10-18 | Biogen Idec Ma Inc. | Isolation and use of human regulatory t cells |
| US20080085532A1 (en) | 2006-09-18 | 2008-04-10 | Jorn Gorlach | Method for determining the immune status of a subject |
| US8043822B2 (en) | 2006-11-02 | 2011-10-25 | Kyowa Medex Co., Ltd. | Method of immunoassaying a component to be measured |
| WO2008140573A2 (en) | 2006-11-15 | 2008-11-20 | Invitrogen Dynal As | Methods for reversibly binding a biotin compound to a support |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| CL2007003622A1 (es) | 2006-12-13 | 2009-08-07 | Medarex Inc | Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales. |
| CN101226118B (zh) | 2007-01-19 | 2010-06-16 | 中国医学科学院肿瘤研究所 | 一种兼容免疫荧光分析的细胞化学染色方法及其用途 |
| PT2856876T (pt) | 2007-03-30 | 2018-03-28 | Memorial Sloan Kettering Cancer Center | Expressão constitutiva de ligantes co-estimulatórios em linfócitos t adotivamente transferidos |
| EP2167536A1 (en) * | 2007-07-03 | 2010-03-31 | Dako Denmark A/S | Mhc multimers, methods for their generation, labeling and use |
| AU2008282152B2 (en) | 2007-07-31 | 2013-12-19 | Regeneron Pharmaceuticals, Inc. | Human antibodies to human CD20 and method of using thereof |
| DK2520643T3 (da) | 2007-12-07 | 2020-01-20 | Miltenyi Biotec Bv & Co Kg | Prøvebehandlingssystemer og -fremgangsmåder |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| JP5781767B2 (ja) | 2008-01-18 | 2015-09-24 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 体液中における疾患または状態のシグネチャーを検出する方法 |
| JP2011510653A (ja) | 2008-01-29 | 2011-04-07 | フレッド ハッチンソン キャンサー リサーチ センター | ＣＤ１６１ｈｉおよび／またはＩＬ１８Ｒａｈｉであり、迅速な薬剤流出能力を有するＣＤ８＋Ｔ細胞の同定 |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
| EP2363501A1 (en) | 2010-03-02 | 2011-09-07 | Universitätsklinikum Hamburg-Eppendorf | Method for isolating target cells |
| CA2806440A1 (en) | 2010-08-06 | 2012-02-09 | Ludwig-Maximilians-Universitaet Muenchen | Identification of t cell target antigens |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| HUE045766T2 (hu) | 2010-12-14 | 2020-01-28 | Glaxosmithkline Biologicals Sa | Antigén mycobacterium-készítmény |
| CN103458904B (zh) | 2010-12-16 | 2016-09-28 | 株式会社明治 | 格氏乳杆菌的菌体级分在制造用于减轻迟发型变态反应的组合物中的用途 |
| BR112013024395B1 (pt) * | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
| LT2837680T (lt) | 2011-07-01 | 2020-07-10 | Amgen Inc. | Žinduolių ląstelių kultūra |
| SI2734538T2 (sl) | 2011-07-18 | 2024-10-30 | Iba Lifesciences Gmbh | Postopek za reverzibilno obarvanje tarčne celice |
| US9353161B2 (en) * | 2011-09-13 | 2016-05-31 | Uti Limited Partnership | Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins |
| WO2013062365A2 (ko) * | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| EP3594245A1 (en) * | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| US10228312B2 (en) | 2012-02-23 | 2019-03-12 | Juno Therapeutics Gmbh | Chromatographic isolation of cells and other complex biological materials |
| EP2859093A4 (en) * | 2012-06-11 | 2016-08-17 | Wolf Wilson Mfg Corp | IMPROVED METHODS FOR CELL CULTURES FOR ADOPTIVE CELL THERAPIES |
| WO2013192294A1 (en) | 2012-06-20 | 2013-12-27 | Boston 3T Biotechnologies, Inc. | Cellular therapies for treating and preventing cancers and other immune system disorders |
| CN104884095A (zh) | 2012-07-13 | 2015-09-02 | 宾夕法尼亚大学董事会 | Cart19用于耗减正常b细胞以诱导耐受的用途 |
| AU2013289979A1 (en) | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Methods of assessing the suitability of transduced T cells for administration |
| SMT202100005T1 (it) | 2012-08-20 | 2021-05-07 | Hutchinson Fred Cancer Res | Metodo e composizioni per immunoterapia cellulare |
| JP6408993B2 (ja) | 2012-09-07 | 2018-10-17 | ジェネンテック， インコーポレイテッド | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
| EP2903637B1 (en) | 2012-10-02 | 2019-06-12 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| EP2906935B1 (en) | 2012-10-12 | 2018-04-04 | Sage Science, Inc. | Side-eluting molecular fractionator |
| CN105073770B (zh) | 2012-11-16 | 2019-08-06 | Iba股份有限公司 | 链霉亲和素突变蛋白及其使用方法 |
| JP5372297B1 (ja) | 2012-12-20 | 2013-12-18 | 三菱電機株式会社 | 車載装置及びプログラム |
| PL3300745T3 (pl) | 2013-02-15 | 2020-03-31 | The Regents Of The University Of California | Chimeryczny receptor antygenowy i sposoby jego zastosowania |
| EP3811954A1 (en) | 2013-02-26 | 2021-04-28 | Memorial Sloan Kettering Cancer Center | Compositions and methods for immunotherapy |
| WO2014165707A2 (en) | 2013-04-03 | 2014-10-09 | Memorial Sloan-Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| US9629877B2 (en) | 2013-05-14 | 2017-04-25 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
| CN103305464B (zh) * | 2013-06-05 | 2015-04-15 | 南昌大学 | 直接分离cd4+和cd8+淋巴细胞的方法 |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| CA2933707A1 (en) | 2013-12-20 | 2015-06-25 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
| ES2876263T3 (es) | 2014-04-07 | 2021-11-12 | Novartis Ag | Tratamiento del cáncer usando receptor de antígeno quimérico anti-cd19 |
| NZ739448A (en) | 2014-04-10 | 2019-10-25 | Seattle Children’S Hospital Dba Seattle Children’S Res Institute | Transgene genetic tags and methods of use |
| PT3132247T (pt) | 2014-04-16 | 2021-11-03 | Juno Therapeutics Gmbh | Métodos, kits e aparelho para ampliar uma população de células |
| WO2015164594A1 (en) | 2014-04-23 | 2015-10-29 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) for use in therapy and methods for making the same |
| RU2763795C2 (ru) * | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| ES2708584T3 (es) | 2014-04-24 | 2019-04-10 | Miltenyi Biotec Gmbh | Método para la generación automatizada de células T modificadas genéticamente |
| AU2015249376C1 (en) | 2014-04-25 | 2019-10-31 | 2Seventy Bio, Inc. | Improved methods for manufacturing adoptive cell therapies |
| CA2984484C (en) | 2014-05-02 | 2024-01-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| EP3174546B1 (en) | 2014-07-31 | 2019-10-30 | Novartis AG | Subset-optimized chimeric antigen receptor-containing t-cells |
| TWI751102B (zh) | 2014-08-28 | 2022-01-01 | 美商奇諾治療有限公司 | 對ｃｄ１９具專一性之抗體及嵌合抗原受體 |
| WO2016061416A1 (en) | 2014-10-15 | 2016-04-21 | Sage Science, Inc. | Apparatuses, methods and systems for automated processing of nucleic acids and electrophoretic sample preparation |
| EP3215168B1 (en) | 2014-10-31 | 2023-08-02 | The Trustees of the University of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
| SG10202002324SA (en) | 2014-11-05 | 2020-05-28 | Juno Therapeutics Inc | Methods for transduction and cell processing |
| WO2016090190A1 (en) | 2014-12-03 | 2016-06-09 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| JP7098325B2 (ja) | 2014-12-05 | 2022-07-11 | シティ・オブ・ホープ | Ｃｓ１標的化キメラ抗原レセプター改変ｔ細胞 |
| AU2015360845B2 (en) | 2014-12-12 | 2020-11-26 | 2Seventy Bio, Inc. | BCMA chimeric antigen receptors |
| RU2751362C2 (ru) | 2014-12-29 | 2021-07-13 | Новартис Аг | Способы получения экспрессирующих химерный антигенный рецептор клеток |
| DE102015205759A1 (de) | 2015-03-31 | 2016-10-06 | Henkel Ag & Co. Kgaa | Mittel für keratinhaltige Fasern, enthaltend mindestens ein Copolymer auf Basis von Vinylpyrrolidon und mindestens ein Copolymer aus Basis von Acrylaten |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| HUE059218T2 (hu) | 2015-04-08 | 2022-11-28 | Novartis Ag | CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel |
| HK1256130A1 (zh) | 2015-07-21 | 2019-09-13 | City Of Hope | 用於嵌合抗原受体和其他受体的表达的t细胞 |
| SG10201912978PA (en) | 2015-07-21 | 2020-02-27 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| MA45488A (fr) | 2015-10-22 | 2018-08-29 | Juno Therapeutics Gmbh | Procédés, kits et appareil de culture de cellules |
| EP3383892B1 (en) | 2015-12-03 | 2022-12-21 | Juno Therapeutics, Inc. | Modified chimeric receptors and related compositions and methods |
| WO2017156479A1 (en) | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| WO2017157505A1 (en) | 2016-03-17 | 2017-09-21 | Merck Patent Gmbh | Method for purifying poloxamers |
| CA3015369A1 (en) | 2016-03-18 | 2017-09-21 | Oliver Press | Compositions and methods for cd20 immunotherapy |
| MX2019006438A (es) | 2016-12-05 | 2019-11-28 | Juno Therapeutics Inc | Produccion de celulas modificadas para terapia de celulas adoptivas. |
| EP3346001A1 (en) | 2017-01-06 | 2018-07-11 | TXCell | Monospecific regulatory t cell population with cytotoxicity for b cells |
| CN110709700A (zh) | 2017-04-14 | 2020-01-17 | 朱诺治疗学股份有限公司 | 评估细胞表面糖基化的方法 |
| CN107723275B (zh) | 2017-10-20 | 2020-09-04 | 重庆精准生物技术有限公司 | 通用型car-t细胞及其制备方法和应用 |
| DK3704230T3 (da) | 2017-11-01 | 2025-01-02 | Juno Therapeutics Inc | Fremgangsmåde til generering af terapeutiske sammensætninger af modificerede celler |
| KR102853341B1 (ko) | 2017-12-08 | 2025-09-02 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작된 ｔ 세포의 조성물을 제조하는 방법 |
| WO2020033927A2 (en) | 2018-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| CN115361955A (zh) | 2020-02-12 | 2022-11-18 | 朱诺治疗学股份有限公司 | 针对bcma的嵌合抗原受体t细胞组合物及其方法和用途 |
| WO2021163391A1 (en) | 2020-02-12 | 2021-08-19 | Juno Therapeutics, Inc. | Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof |
-
2015
- 2015-04-23 RU RU2016145424A patent/RU2763795C2/ru active
- 2015-04-23 EP EP19197801.4A patent/EP3647412A1/en not_active Withdrawn
- 2015-04-23 WO PCT/US2015/027401 patent/WO2015164675A1/en not_active Ceased
- 2015-04-23 IL IL292038A patent/IL292038B2/en unknown
- 2015-04-23 PL PL23164036.8T patent/PL4219687T3/pl unknown
- 2015-04-23 KR KR1020247033230A patent/KR20240149454A/ko active Pending
- 2015-04-23 IL IL313845A patent/IL313845A/en unknown
- 2015-04-23 EP EP15721094.9A patent/EP3134514B1/en active Active
- 2015-04-23 SG SG11201608862SA patent/SG11201608862SA/en unknown
- 2015-04-23 US US15/305,337 patent/US11400115B2/en active Active
- 2015-04-23 EP EP24194366.1A patent/EP4450615A3/en active Pending
- 2015-04-23 MA MA039867A patent/MA39867A/fr unknown
- 2015-04-23 ES ES15721094T patent/ES2759260T3/es active Active
- 2015-04-23 ES ES23164036T patent/ES2995052T3/es active Active
- 2015-04-23 CN CN202110191715.XA patent/CN113046312A/zh active Pending
- 2015-04-23 KR KR1020167032823A patent/KR102447958B1/ko active Active
- 2015-04-23 MX MX2016013747A patent/MX382541B/es unknown
- 2015-04-23 CA CA2946312A patent/CA2946312A1/en not_active Abandoned
- 2015-04-23 MA MA051794A patent/MA51794A/fr unknown
- 2015-04-23 CN CN201580034318.4A patent/CN106459917B/zh active Active
- 2015-04-23 CN CN202110191749.9A patent/CN113046321A/zh active Pending
- 2015-04-23 BR BR112016024579A patent/BR112016024579A2/pt not_active Application Discontinuation
- 2015-04-23 DK DK23164036.8T patent/DK4219687T3/da active
- 2015-04-23 PT PT231640368T patent/PT4219687T/pt unknown
- 2015-04-23 JP JP2017507920A patent/JP6759187B2/ja active Active
- 2015-04-23 KR KR1020227032825A patent/KR20220136455A/ko not_active Ceased
- 2015-04-23 AU AU2015249554A patent/AU2015249554B2/en active Active
- 2015-04-23 FI FIEP23164036.8T patent/FI4219687T3/fi active
- 2015-04-23 EP EP23164036.8A patent/EP4219687B1/en active Active
-
2016
- 2016-10-19 MX MX2021005625A patent/MX2021005625A/es unknown
- 2016-10-21 PH PH12016502112A patent/PH12016502112A1/en unknown
- 2016-10-23 SA SA516380118A patent/SA516380118B1/ar unknown
- 2016-10-23 IL IL24845116A patent/IL248451B/en active IP Right Grant
-
2019
- 2019-09-18 IL IL269440A patent/IL269440B/en active IP Right Grant
-
2020
- 2020-06-01 JP JP2020095186A patent/JP7181910B2/ja active Active
-
2021
- 2021-02-09 IL IL280743A patent/IL280743B/en unknown
- 2021-07-27 AU AU2021209195A patent/AU2021209195B2/en active Active
- 2021-08-23 JP JP2021135398A patent/JP7503035B2/ja active Active
-
2022
- 2022-06-27 US US17/850,875 patent/US20230090176A1/en active Pending
-
2023
- 2023-02-08 US US18/166,447 patent/US12208137B2/en active Active
-
2024
- 2024-03-19 JP JP2024043330A patent/JP7675243B2/ja active Active
- 2024-04-12 AU AU2024202424A patent/AU2024202424A1/en active Pending
- 2024-12-16 US US18/983,137 patent/US12296010B2/en active Active
-
2025
- 2025-01-17 US US19/029,968 patent/US20250152712A1/en active Pending
- 2025-01-17 US US19/030,019 patent/US20250161449A1/en active Pending
- 2025-01-17 US US19/030,056 patent/US20250161450A1/en active Pending
- 2025-04-25 JP JP2025072785A patent/JP2025108747A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514517A5 (cg-RX-API-DMAC7.html) | ||
| RU2016145424A (ru) | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии | |
| JP7665579B2 (ja) | 細胞の培養方法ならびにそのためのキットおよび装置 | |
| JP7654702B2 (ja) | キメラ抗原受容体及び他の受容体の発現に対するｔ細胞 | |
| JP7122336B2 (ja) | 自己癌抗原特異的ｃｄ８＋ｔ細胞の分離及び増殖方法 | |
| JP7604366B2 (ja) | 遺伝子操作されたｔ細胞を作製するための方法 | |
| JP2020500563A5 (cg-RX-API-DMAC7.html) | ||
| JP2020532954A5 (cg-RX-API-DMAC7.html) | ||
| Jiang et al. | Intact CD100–CD72 interaction necessary for TCR-induced T cell proliferation | |
| WO2020148769A1 (en) | Biomarker for cns disease modification | |
| JP2023526278A (ja) | 組み換え受容体を発現しているドナーバッチ細胞を産生するための方法 | |
| CA3087948A1 (en) | Compositions and methods of expansion of t cell populations | |
| WO2020191378A1 (en) | METHODS FOR ENHANCING TCRαβ+ CELL DEPLETION EFFICIENCY | |
| KR20250011210A (ko) | 고 cd16 고 cd57 nk-92mi 세포 | |
| Fang et al. | Tumor Necrosis Factor-α Pathway Plays a Critical Role in Regulating Interferon-γ Induced Protein-10 Production in Initial Allogeneic Human Monocyte–Endothelial Cell Interactions | |
| JP2019508056A5 (cg-RX-API-DMAC7.html) | ||
| Langa et al. | Enrichment of CD4+ and CD8+ T lymphocytes with a column-free flow-based device for clinical cell manufacturing | |
| AU2021401934A1 (en) | Methods and reagents for characterizing car t cells for therapies | |
| Chen et al. | Transient-resting culture after activation enhances the generation of CD8+ stem cell-like memory T cells from peripheral blood mononuclear cells | |
| Wang et al. | Establishing cGMP manufacturing of CRISPR/Cas9-edited human CAR T cells | |
| RU2021136264A (ru) | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии | |
| Wu et al. | Efficient and Traceless Aptamer‐Based Serial Selection of Naïve and Early Memory CD8 T Cells for CAR T Cell Therapy | |
| EP1751661A2 (en) | Method for selectively expanding, selecting and enriching stem/progenitor cell populations | |
| US20230407252A1 (en) | Methods for donor cell analysis | |
| WO2024040201A1 (en) | Improved method and system for cell therapy |